NYSE
281.38USD
+0.35 (+0.12%)
We have scored 47 news catalysts on Cigna Corporation (CI) over the past 12 months. The biggest single-day move next to one of them came Nov 24, 2025, when CI closed −2.4%: “Cigna: Now Is A Prime Buying Opportunity”. Coverage across the window leans positive (average ticker sentiment +0.30). Most of the impact sits in sector healthcare and factor value.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
74.6B
P/E
—
EPS
—
Beta
0.30
52W range
239.51-311.34
Day range
280.46–287.42
Open
281.16
Prev close
281.03
Volume
246.5K
Avg volume
1.7M
Dividend
6.19
IPO
1982-03-31
Analysts publish price targets on CI, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
9 analyst price targets from $304 to $381
as of 2026-09-23
The market is 14% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cigna Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Cigna Corporation, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions. These offerings cater to a diverse clientele, such as health plans, employers, government entities, and healthcare providers. Meanwhile, the Cigna Healthcare segment delivers an extensive portfolio of products and services, encompassing medical, pharmaceutical, behavioral health, dental, vision, and health advocacy programs for both insured and self-insured customers. This segment also provides Medicare Advantage, Medicare Supplement, and Medicare Part D plans specifically for seniors, in addition to individual health insurance options available on and off public exchanges. Globally, Cigna Healthcare extends international health coverage and benefits to mobile professionals and employees of multinational organizations. Furthermore, the company issues permanent insurance contracts to corporations, designed to cover the lives of specific employees for funding future benefit obligations. Cigna distributes its various offerings through insurance brokers and consultants, direct sales channels to employers, unions, and individuals, and via both private and public exchanges.
The price sits 14% below the median analyst target and at the very bottom of the published range, meaning the market completely rejects the bullish consensus and prices in a severe growth deceleration from the 11.3% just delivered.
What the disagreement turns on
Does Evernorth's specialty growth continue at or near its recent pace, or does it decelerate so sharply that the company's overall revenue actually contracts? Unit volume data for Evernorth can settle this, and it is measurable.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
